Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07728097

A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS

This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Lennox-Gastaut Syndrome Brain Diseases Central Nervous System Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Epilepsy Epileptic Syndromes Genetic Diseases, Inborn Lennox Gastaut Syndrome Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Louisiana State University Health Sciences Center New Orleans

New Orleans, Louisiana, 70112, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has a confirmed clinical diagnosis of LGS with a history of seizures and actively experiencing seizures within 6 months of screening.
  • Is naïve to CBD-OS treatment or has been off CBD-OS treatment for at least 3 months prior to screening.
  • Is willing to maintain any factors expected to affect seizures (eg, alcohol consumption, smoking, concomitant medication usage) stable for the duration of the study.
  • Is currently treated with at least 1 ASM, but no more than 3 ASMs, and is on a stable regimen for at least 4 weeks prior to screening.
  • Adequate contraceptive precautions
  • Participant has a primary caregiver/legally authorized representative (LAR) who is willing and able, in the investigator's opinion, to participate throughout the duration of the study and to comply with all study requirements
  • Experienced at least 4 or more countable major motor seizures (isolated seizures or seizures occurring in a cluster) during the 5-week Baseline Period preceding treatment.
  • Caregiver completed at least 80% of seizure diary entries during the Baseline Period with no more than 3 consecutive days of missing entries.

Exclusion criteria

  • Has a significant psychiatric illness
  • Has an illness during the 4 weeks prior to screening other than epilepsy which, in the investigator's opinion, could affect study outcomes or seizure frequency.
  • Has history of SE in the 3 months prior to screening.
  • Has any other significant disease other than epilepsy, which, in the investigator's opinion, may either put the participant, other participants, or site staff at risk because of participation in the study, may influence the result of the study, or may affect the participant's ability to take part in the study.
  • Has previously undergone significant surgery for epilepsy in the 6 months prior to screening or planned to undergo surgery for epilepsy during the study.
  • Is currently using or has in the past used recreational or medicinal cannabis or synthetic cannabinoid-based medications, products, or supplements within the 3 months prior to screening and is not willing to undergo a 1-month washout period before being rescreened.
  • Has initiated felbamate within the 12 months prior to screening.
  • Is not willing to adjust dosage of CBD-OS if needed when using strong inducers of CYP3A4 and/or strong inducers of CYP2C19 concomitantly with CBD-OS
  • Previously discontinued cannabidiol due to severe adverse events (SAE), hypersensitivity or lack of efficacy
  • Has clinically significant abnormal lab values
  • Has clinically impaired hepatic or renal function
  • History of, current risk or presence of actual suicidal ideations
  • Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of CBD-OS, such as sesame oil.
  • Has a known or suspected history of alcohol or substance abuse disorder
  • Is currently consuming, and unwilling to stop consumption, or planning to consume tonic water on a regular basis throughout the study.

Treatment and study plan

Cannabidiol Oral Solution

Drug

100 mg/ml Cannabidiol Oral solution (CBD-OS)

Other names: JZP926, CBD-OS, Epidiolex, Epidyolex

Primary outcomes

  1. Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequency

    Time frame: End of Treatment Period, Week 24

Secondary outcomes

  1. Retention Rate

    Time frame: At Weeks 8, 12, 16 and 24

    Retention Rate is defined as percentage of participants completing or continuing CBD-OS treatment at different timepoints in the study

  2. Percentage of participants experiencing worsening, change, no change or improvement in in their 28-day average countable major motor and total seizure frequency

    Time frame: Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24

    As reported in participants' electronic diaries

  3. Percentage of participants considered treatment responders

    Time frame: Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24

    Treatment responders will be categorized as those experiencing a 50% or more reduction, a 75% or more reduction or 100% reduction in their 28-day average seizure frequency as reported in participants' electronic diaries

  4. Change in 28-day average frequency of countable major motor and total seizures

    Time frame: Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24

    Assessed per 28 days from electronic diary entries

  5. Change in number of seizure-free days

    Time frame: Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24

    Assessed per 28 days from electronic diary entries

  6. Change in CaGI-S severity of seizure scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Caregiver Global Impression of Severity (CaGI-S) is a single-item, 5-point Likert-type rating scale (ranging from 0 "not severe at all" to 5 "very severe"). Using this scale, caregivers will be asked to rate their impression of the participant's severity of seizures, and the severity of the impact caused by the seizure.

  7. Change in CaGI-S severity of impact of seizures scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Caregiver Global Impression of Severity (CaGI-S) is a single-item, 5-point Likert-type rating scale (ranging from 0 "not severe at all" to 5 "very severe"). Using this scale, caregivers will be asked to rate their impression of the participant's severity of the impact caused by the seizure.

  8. Change in VAS scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Visual Analog Scale (VAS) is a caregiver-reported tool used to quantify the severity of impact of subjective non-seizure symptoms and assesses sleep, communication, and disruptive behavior. The VAS enables sensitive detection of changes in non-seizure domains (disruptive behavior, Sleep, and Communication) important to patients with LGS and their caregivers. The VAS has a total score ranging from 0 to 100 with the higher score indicating worse conditions.

  9. Change in CaGI-S severity of level of alertness scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    CaGI-S Alertness is a caregiver single item assessment on a 5-point Likert-type rating scale (ranging from 0 "not severe at all" to 5 "very severe") assessing their impression of participant's severity of level of awareness

  10. Change in CaGI-S severity of overall condition scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    CaGI-S Overall Condition is a caregiver single item assessment on a 5-point Likert-type rating scale (ranging from 0 "not severe at all" to 5 "very severe") assessing their impression of participant's severity of overall condition

  11. CaGI-C level of alertness scores

    Time frame: At Week 16, at week 24

    Caregiver Global Impression of Change (CaGI-C) Alertness is a caregiver single item assessment on a 7-point Likert-type rating scale (ranging from 1 "very much improved" to 7 "very severe") assessing their impression of participant's severity of level of awareness

  12. CaGI-C overall condition scores

    Time frame: At Week 16, at week 24

    Caregiver Global Impression of Change (CaGI-C) overall condition is a caregiver single item assessment on a 7-point Likert-type rating scale (ranging from 1 "very much improved" to 7 "very severe") assessing their impression of participant's severity of overall condition

  13. Change in CGI-S overall condition scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Clinician Global Impression of severity (CGI-S) Overall Condition is a clinician single item assessment on a 5-point Likert-type rating scale (ranging from 1 "not severe at all" to 5 "very severe") assessing their impression of participant's severity of level of overall condition

  14. CGI-C overall condition scores

    Time frame: At Week 16, At Week 24

    Clinician Global Impression of Change (CGI-C) Overall Condition is a clinician single item assessment on a 7-point Likert-type rating scale (ranging from 1 "very much improved" to 5 "very much worse") assessing their impression of participant's change of overall condition

  15. Change in ELDQOL Behavior subscale scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Epilepsy and Learning Disabilities Quality of Life (ELDQOL) is designed for the caregiver to rate the quality of life (QOL) in children with severe epilepsy and learning disabilities over the last month. The questionnaire has a total of 28 main questions, grouped into 4 subscales: behavior, seizure severity, mood, and side effects. The ELDQOL behavior subscale includes 9 of the 28 total main questions with a total score ranging from 9 to 36 with the higher score indicating greater behavioral problems

  16. Change in ELDQOL seizure severity subscale scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Epilepsy and Learning Disabilities Quality of Life (ELDQOL) is designed for the caregiver to rate the quality of life (QOL) in children with severe epilepsy and learning disabilities over the last month. The questionnaire has a total of 28 main questions, grouped into 4 subscales: behavior, seizure severity, mood, and side effects. The ELDQOL seizure severity subscale includes 14 of the 28 total main questions with a total score ranging from 10 to 56 with the higher score indicating greater seizure severity

  17. Change in ELDQOL mood scale subscale scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Epilepsy and Learning Disabilities Quality of Life (ELDQOL) is designed for the caregiver to rate the quality of life (QOL) in children with severe epilepsy and learning disabilities over the last month. The questionnaire has a total of 28 main questions, grouped into 4 subscales: behavior, seizure severity, mood, and side effects. The ELDQOL mood scale subscale includes 1 of the 28 total questions with a total score ranging from 16 to 64 with the higher score indicating greater mood problems

  18. Change in ELDQOL side-effects profile subscale scores

    Time frame: Baseline to Week 16, Baseline to Week 24

    Epilepsy and Learning Disabilities Quality of Life (ELDQOL) is designed for the caregiver to rate the quality of life (QOL) in children with severe epilepsy and learning disabilities over the last month. The questionnaire has a total of 28 main questions, grouped into 4 subscales: behavior, seizure severity, mood, and side effects. The ELDQOL side-effects profile subscale includes 2 of the 28 total main questions with a score ranging from 19 to 76 with the higher score indicating greater side effects

  19. Number of participants reporting adverse events leading to discontinuation

    Time frame: Up to week 24

  20. Time the adverse events started from baseline

    Time frame: Up to week 24

  21. Number of Participants with Abnormal Laboratory Values

    Time frame: Up to week 24

  22. Change in suicidal ideation scores

    Time frame: Baseline, up to week 24

    As evaluated by the Columbia-Suicide Severity Rating Scale (C-SSRS). The questionnaire has a total score ranging from 0 to 5 with a score of 0 indicating no suicidal ideation is present.

  23. Change in number of suicide attempts

    Time frame: Baseline, up to week 24

    As per the response in the C-SSRS

  24. Percentage of participants requiring inpatient hospitalization due to epilepsy

    Time frame: Up to week 24

  25. Change in number of usage of rescue medication

    Time frame: Baseline, Up to week 24

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trial Disclosure & Transparency

CONTACT

[email protected]

215-832-3750

Sponsors and collaborators

Lead sponsor

Jazz Pharmaceuticals

Industry

Collaborators

  • Jazz Pharmaceuticals Research UK Limited

Registry information

Official study title

A Phase 3b/4, Interventional, Prospective, Multicenter, Open-Label Study Evaluating the Effectiveness of a Gradual Titration Regimen to Optimize CBD-OS as Add-On Therapy in Adults With Lennox-Gastaut Syndrome

Acronym: EpiGOAL

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 27, 2026
Registry last updated
Jul 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.